EU clears Abbott's blood test for ovarian cancer

01/16/2010 | Clinica (subscription required)

Abbott Laboratories has received EU's CE Mark approval for Architect HE4, a blood test designed to help determine whether pelvic masses are benign or cancerous. The company says its product, co-developed with Fujirebio Diagnostics, is the world's first automated HE4 diagnostic. Abbott also filed an application with the FDA seeking 510(k) clearance for the test.

View Full Article in:

Clinica (subscription required)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI